Compass Pathways raises 146 millions dollars to develop psilocybin therapies

[knakoo]

Compass Pathways raised Hundred of millions of dollars (146 m$ in recent IPO) to develop psilocybin therapies. Can someone explain to me what will be the benefits for them to raise so much money ? Running clinical trials is that expensive ? 

How does a company in the psychedelic sector will be able to have and keep an edge on the competition ? What is the barrier to entry ? Is it all about being first and building a brand ? 

They have a patent for their "psilocybin formulation", COMP360. Is that different from other synthesised psilocybin ? Cheaper to produce maybe ? Because in the end you can't patent psilocybin, can you ? 

Do you expect these companies will create amazing new psychedelics in the future ?

 

[knakoo]

Following is an interesting article about potential issues with the company :

https://qz.com/1454785/a-millionaire-couple-is-threatening-to-create-a-magic-mushroom-monopoly/

[OBEler]

There are other stocks like mind medicine which are more interesting, but different treatment (addiction vs depression).

I dont agree with potential issues in terms of compass Pathways. In case of mushrooms just set and setting must be right. If the therapeut has no idea about psychedelics, fine. Mushrooms will help anyway with depression